Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
The impact of, and expectations for, lipid nanoparticle technology: From cellular targeting to organelle targeting
Ist Teil von
Journal of controlled release, 2024-05, Vol.370, p.516-527
Ort / Verlag
Netherlands: Elsevier B.V
Erscheinungsjahr
2024
Link zum Volltext
Quelle
Alma/SFX Local Collection
Beschreibungen/Notizen
The success of mRNA vaccines against COVID-19 has enhanced the potential of lipid nanoparticles (LNPs) as a system for the delivery of mRNA. In this review, we describe our progress using a lipid library to engineer ionizable lipids and promote LNP technology from the viewpoints of safety, controlled biodistribution, and mRNA vaccines. These advancements in LNP technology are applied to cancer immunology, and a potential nano-DDS is constructed to evaluate immune status that is associated with a cancer-immunity cycle that includes the sub-cycles in tumor microenvironments. We also discuss the importance of the delivery of antigens and adjuvants in enhancing the cancer-immunity cycle. Recent progress in NK cell targeting in cancer immunotherapy is also introduced. Finally, the impact of next-generation DDS technology is explained using the MITO-Porter membrane fusion-based delivery system for the organelle targeting of the mitochondria. We introduce a successful example of the MITO-Porter used in a cell therapeutic strategy to treat cardiomyopathy.
[Display omitted]
•The efficiency of lipid nanoparticles is discussed from the viewpoint of a 3-dimensinal structure of ionizable lipids based on critical packing parameters relative to endosomal escape.•A potential nano-DDS is designed based on a cancer immunity cycle that includes sub-cycles in a tumor microenvironment, and a NK cell targeting strategy is also introduced.•As a next-generation DDS technology, MITO-Porter was introduced as an organelle-targeting DDS that was successfully applied to cardiac progenitor cell transplantation therapy.